R2530
罗匹尼罗 盐酸盐
≥98% (HPLC), D2 and D3 dopamine receptor agonist, powder
别名:
SKF 101468 hydrochloride, 4-[2-(Dipropylamino)ethyl]-1,3-dihydro-2H-indol-2-one hydrochloride
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C16H24N2O · HCl
化学文摘社编号:
分子量:
296.84
UNSPSC Code:
12352200
PubChem Substance ID:
NACRES:
NA.77
MDL number:
产品名称
罗匹尼罗 盐酸盐, powder, ≥98% (HPLC)
SMILES string
Cl.CCCN(CCC)CCc1cccc2NC(=O)Cc12
InChI key
XDXHAEQXIBQUEZ-UHFFFAOYSA-N
InChI
1S/C16H24N2O.ClH/c1-3-9-18(10-4-2)11-8-13-6-5-7-15-14(13)12-16(19)17-15;/h5-7H,3-4,8-12H2,1-2H3,(H,17,19);1H
assay
≥98% (HPLC)
form
powder
storage condition
desiccated
color
light yellow
solubility
H2O: >10 mg/mL
originator
GlaxoSmithKline
Quality Level
Gene Information
human ... DRD2(1813), DRD3(1814), DRD4(1815)
正在寻找类似产品? 访问 产品对比指南
Biochem/physiol Actions
An agonist at the D2 and D3 dopamine receptor subtypes, binding with higher affinity to D3 than to D2 or D4. It has negligible effect on D1-receptors. It has medium in vitro affinity to opioid receptors. Ropinirole is said to have virtually no affinity to 5-HT1, 5-HT2, benzodiazepine, GABA, muscarinic, α1-, α2-, and β-adrenoreceptors. Used as antiparkinsonian drug.
Ropinirole hydrochloride is effectively used to treat early and late Parkinson′s disease.
Selective D2 dopamine receptor agonist, antiparkinsonian
Features and Benefits
This compound is featured on the Dopamine Receptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by GlaxoSmithKline. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
signalword
Warning
hcodes
Hazard Classifications
Acute Tox. 4 Oral - Aquatic Acute 1
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
dust mask type N95 (US), Eyeshields, Faceshields, Gloves
法规信息
新产品
此项目有
N Hattori et al.
Journal of clinical pharmacy and therapeutics, 37(5), 571-577 (2012-03-07)
Ropinirole hydrochloride, a dopamine receptor agonist with a non-ergot alkaloid structure, is highly selective for the dopamine D(2) /D(3) receptors. This study was conducted to evaluate the steady-state pharmacokinetics, safety and efficacy after repeated oral administration of prolonged-release tablets of
Francisco J Zagmutt et al.
The International journal of neuroscience, 122(7), 345-353 (2012-02-07)
The comparative safety profiles of monotherapeutic treatments for Parkinson's disease (PD) can provide valuable therapeutic information. The objective of this study was to perform an indirect comparison of Adverse Events (AEs) and Dropout Rates (DRs) among clinical trials of pramipexole
Dopamine agonist withdrawal syndrome in a patient with restless legs syndrome.
Benjamin J Dorfman et al.
Parkinsonism & related disorders, 19(2), 269-270 (2012-07-04)
T Nissen et al.
Scottish medical journal, 57(4), 217-220 (2012-09-25)
The expected duration of initial antiparkinson monotherapy before the need for supplementation is not clearly defined for routine practice. The aim of this study was to define the length of L-dopa (L-3, 4-dihydrophenylalanine) and dopamine agonist monotherapy. The duration of
Sébastien Duband et al.
Journal of forensic and legal medicine, 19(7), 422-425 (2012-08-28)
Ropinirole, a specific non-ergoline dopamine D2-receptor agonist, belongs to the drugs applied in treatment of Parkinson's disease (PD) and restless legs syndrome (RLS) and acts as a D2, D3, and D4 dopamine receptor agonist with highest affinity for D3. Therapeutic
商品
We offer many products related to dopamine receptors for your research needs.
我们可提供多种多巴胺受体相关的产品，满足您的各类研究需求。
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持